With Bayer deal ended, Evotec mulls options, plots future with newer platforms

As Evotec considers the future of a clinical P2X3 program to which Bayer returned rights this month, the discovery-oriented biotech is looking to its newer platforms as it maps out a path to future partnerships.

Shares of Evotec SE (Xetra:EVT; NASDAQ:EVO) have fallen by more than 20% since the biotech said Feb. 3 that Bayer AG (Xetra:BAYN) would return rights to eliapixant, which had reached Phase II testing in four indications. The pharma had concluded that the P2X3 receptor antagonist’s benefits no longer outweighed its risks; a Bayer spokesperson declined further comment to BioCentury...